Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
Big Pharma Split Corp Class A (PRM) - Total Assets
Latest total assets as of June 2025: CA$25.77 Million CAD
Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) holds total assets worth CA$25.77 Million CAD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Big Pharma Split Corp Class A - Total Assets Trend (2017–2024)
This chart illustrates how Big Pharma Split Corp Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Big Pharma Split Corp Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Big Pharma Split Corp Class A's total assets of CA$25.77 Million consist of 4.3% current assets and 95.7% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 3.9% |
| Accounts Receivable | CA$96.74K | 0.4% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Big Pharma Split Corp Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Big Pharma Split Corp Class A's current assets represent 4.3% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 5.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Big Pharma Split Corp Class A Competitors by Total Assets
Key competitors of Big Pharma Split Corp Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
India | ₹16.78 Billion |
|
Gibui Holdings Ltd
TA:GIBUI
|
Israel | ILA445.00 Million |
|
Digital 9 Infrastructure PLC
LSE:DGI9
|
UK | GBX287.45 Million |
|
Angel Oak Financial Strategies Income Term Trust
NYSE:FINS
|
USA | $486.05 Million |
|
Global Data Centre Group
AU:GDC
|
Australia | AU$151.04 Million |
|
Hearts and Minds Investments Ltd
AU:HM1
|
Australia | AU$857.95 Million |
|
MainStay CBRE Global Infrastructure Megatrends Fund
NYSE:MEGI
|
USA | $1.07 Billion |
|
Nippon Active Value Fund Plc
LSE:NAVF
|
UK | GBX390.96 Million |
Big Pharma Split Corp Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Big Pharma Split Corp Class A generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Big Pharma Split Corp Class A is currently not profitable relative to its asset base.
Big Pharma Split Corp Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.21 | 2.58 | 2.03 |
| Quick Ratio | 0.21 | 2.58 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-9.96 Million | CA$ 16.89 Million | CA$ 12.97 Million |
Big Pharma Split Corp Class A - Advanced Valuation Insights
This section examines the relationship between Big Pharma Split Corp Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | CA$26.30 Million |
| Market Capitalization | $91.16K USD |
Valuation Analysis
Below Book Valuation: The market values Big Pharma Split Corp Class A's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Big Pharma Split Corp Class A's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Big Pharma Split Corp Class A (2017–2024)
The table below shows the annual total assets of Big Pharma Split Corp Class A from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$26.30 Million | -0.88% |
| 2023-12-31 | CA$26.53 Million | -32.13% |
| 2022-12-31 | CA$39.10 Million | +3.39% |
| 2021-12-31 | CA$37.81 Million | +64.89% |
| 2020-12-31 | CA$22.93 Million | -15.62% |
| 2019-12-31 | CA$27.18 Million | -19.19% |
| 2018-12-31 | CA$33.63 Million | +3.52% |
| 2017-12-31 | CA$32.49 Million | -- |